Hologic Completes Acquisition of Endomagnetics Ltd
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725351417/en/
![Endomagnetics breast cancer surgery technologies (Photo: Business Wire)](https://mms.businesswire.com/media/20240725351417/en/2196024/4/Endomag_LI_landscape.jpg)
Endomagnetics breast cancer surgery technologies (Photo: Business Wire)
“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” said
The transaction adds Endomag’s wireless breast surgery localization and lymphatic tracing solutions – including the Magseed® marker, the Magtrace® lymphatic tracer and the Sentimag® platform – to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience.
“We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians,” said
About Hologic
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; strategies, positioning, resources, capabilities, and expectations for future performance; and financial outlook and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Endomag operations with those of Hologic will be greater than expected; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.
The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the
Hologic, The Science of Sure, Magseed, Magtrace and Sentimag are trademarks and/or registered trademarks of
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725351417/en/
Media Contact
Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investor Contact
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
Source: